Edwards Lifesciences Corp. closed 26.14% below its 52-week high of $96.12, which the company reached on March 28th.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...